The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

NEW YORK – Elicio Therapeutics earlier this week said it has reached an agreement with the US Food and Drug Administration on a planned Phase III trial and registrational strategy for its ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

NEW YORK – By the end of a controversial workshop Thursday on whether to test patients for genetic abnormalities that put them at risk of severe chemotherapy-related toxicities, oncologists seemed ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.

NEW YORK – Scientists are working to better understand the role of germline pathogenic variants in the development of ductal carcinoma in situ (DCIS) and whether germline variants influence which ...